Has Terry Shimamoto, MD received payments from drug or device companies?

Yes. Drug and device makers reported $23,606 in general payments to Terry Shimamoto, MD across 1,115 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Terry Shimamoto, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Terry Shimamoto, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Terry Shimamoto, MD

Neurology · Honolulu, HINPI 1174521900

Payments from drug & device makers

$23,606in general payments, 2019–2025

Across 1,115 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$4K
UCB, Inc.$3K
Teva Pharmaceuticals USA, Inc.$2K
AstraZeneca$988
Jazz Pharmaceuticals Inc.$865
Lundbeck LLC$847
plus $13K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	191	$3,863
UCB, Inc.	105	$2,550
Teva Pharmaceuticals USA, Inc.	102	$1,940
AstraZeneca	38	$988
Jazz Pharmaceuticals Inc.	25	$865
Lundbeck LLC	38	$847
Neurocrine Biosciences, Inc.	30	$846
Amgen(2 entities)	34	$816
Pfizer	55	$764
Sunovion Pharmaceuticals Inc.	67	$758
Eisai Inc.	31	$660
Biogen	29	$651
SK Life Science, Inc.	31	$569
Harmony Biosciences LLC	21	$565
Argenx US, Inc.	19	$459
Acadia Pharmaceuticals Inc	21	$453
Neurelis, Inc.	26	$451
Tanabe Pharma America, Inc.	21	$430
Novartis	21	$399
Acorda Therapeutics, Inc	13	$327
Livanova USA, Inc.	6	$313
Amneal Pharmaceuticals LLC	16	$312
CSL Behring	15	$297
Takeda Pharmaceuticals U.S.A., Inc.	10	$278
Biohaven Pharmaceutical Holding Company Ltd.	19	$265
Upsher-smith Laboratories LLC	13	$254
Kyowa Kirin, Inc.	13	$242
EMD Serono, Inc.	10	$226
Otsuka America Pharmaceutical, Inc.	9	$206
Medtronic	3	$155
Grifols USA, LLC	6	$130
Adamas Pharmaceuticals, Inc.	6	$126
Alnylam Pharmaceuticals Inc.	5	$123
Bristol Myers Squibb	6	$118
TG Therapeutics, Inc.	5	$115
Vanda Pharmaceuticals Inc.	3	$105
Lilly USA, LLC	4	$100
Sanofi	4	$98
Biohaven Pharmaceuticals, Inc.	4	$86
Avanir Pharmaceuticals, Inc.	4	$82
Catalyst Pharmaceuticals, Inc.	3	$74
Kowa Pharmaceuticals America, Inc.	4	$71
Arbor Pharmaceuticals, Inc.	4	$65
Axsome Therapeutics, Inc.	2	$54
Merz Pharmaceuticals, LLC	2	$52
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$52
Genentech USA, Inc.	3	$50
Merz North America, Inc.	2	$45
Insightec,inc	2	$44
Greenwich Biosciences, Inc.	2	$40
Amarin Pharma, Inc.	2	$37
Supernus Pharmaceuticals, Inc.	2	$36
Sarepta Therapeutics, Inc.	1	$30
Mallinckrodt Hospital Products Inc.	1	$29
Akcea Therapeutics, Inc.	1	$28
Amylyx Pharmaceuticals, Inc.	1	$24
Impel Pharmaceuticals Inc.	1	$22
Genentech, Inc.	1	$17

How this compares

$23,606 in reported general payments places this provider in the 85th percentile of 54 neurology providers in Hawaii.

See all neurology providers in Hawaii →

Medicare billing

Part B allowed, 2024

$96,591

Medicare patients

449

Services billed

1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Honolulu

Kore LiowHonolulu$8M
Leo MaherHonolulu$382K
Leah RidgeHonolulu$47K
Natalia Gonzalez CalditoHonolulu$37K
Pola ChojeckaHonolulu$34K
Melvin YeeHonolulu$32K
Kevin KimataHonolulu$24K
Michael RussoHonolulu$20K
Fay GaoHonolulu$13K
Sarah GranerHonolulu$10K

See the full list for Hawaii →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →